Compensated Awareness Post View
Disclaimer
Zenosense, Inc. (ZENO) Completes Protocol Design – Lung Cancer Detection Trial on Deck
Zenosense, a healthcare technology company involved in developing and marketing devices to detect MRSA and signs of lung cancer in exhaled breath, has announced the completion of protocol design of a significant lung cancer detection trial. Testing will done in a clinical setting and is subject to agreements with a compatible hospital in the near future.
The aim of the trial is to test the ability of a prototype Zenosense lung cancer detector, currently under development. Clinical tests will divide a total of 400 patients into four groups; smokers, non-smokers, lung cancer patients and those diagnosed with Chronic Obstructive Pulmonary Disease.
There is extensive scientific data which indicates that lung cancer causes alterations in cellular metabolism, due to oxidative stress, resulting in the production of a number of distinctive Volatile Organic Compounds in exhaled breath. The trial looks to identify the lung cancer biomarkers and to determine the adequacy of the Device in detecting these biomarkers, compared to conventional laboratory analysis.
Breath samples will be taken from each subject using a standard breath sampler. They will be captured, stored and analyzed to a strict protocol taking into account ambient air samples. These samples will be analyzed in parallel by conventional laboratory methods including Gas Chromatography (“GC”) and Mass Spectrometry (“MS”); and by two prototype devices of the same design, to ensure device results are copied.
Zenosense is a detection device development company based in Valencia, Spain. ZENO endeavors to develop medical devices targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients. Further, the company looks to market and sell these products to hospitals and primary healthcare facilities. The two devices currently under development are a device intended to detect the Methicillin-resistant Staphylococcus aureus “Super-Bug” (MRSA) and a device intended to detect Lung Cancer. Using a common Electronic Nose technology platform, the devices analyze Volatile Organic Compounds (VOCs), which are present in the exhaled breath of patients, scanning for certain biomarkers which can indicate the presence of infection/illness.
For more information on the company, visit www.zenosense.net
